Nektar TherapeuticsNKTR
13F holders, Q3 2025 (September 30)9holders
2new positions
2sold out
$56.89avg. 13F price*
At the end of Q3 2025, 9 institutions reported holding Nektar Therapeutics (NKTR) in their 13F filings, unchanged from Q2 2025. 2 opened new positions and 2 sold out. The largest holders were 49 Wealth Management, LLC ($340K), Parallel Advisors, LLC ($60K) and EverSource Wealth Advisors, LLC ($6K).
- Company
- Nektar Therapeutics
- CUSIP
- 640268108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $342K |
| Exits | 2 | $99K |
All 13F filers, Q2 2025 → Q3 2025: 6,028 shares bought and 8,948 shares sold, net −2,920 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| 49 Wealth Management, LLC | 0.03% | New | 5,981 | $340K |
| Parallel Advisors, LLC | 0.00% | No change | 1,053 | $60K |
| EverSource Wealth Advisors, LLC | 0.00% | Reduce -86.4% | 110 | $6K |
| Rise Advisors, LLC | 0.00% | Add +40.8% | 69 | $4K |
| Fortitude Family Office, LLC | 0.00% | New | 21 | $1K |
| AllSquare Wealth Management LLC | 0.00% | No change | 18 | $1K |
| Nova Wealth Management, Inc. | 0.00% | Add +60.0% | 16 | $910 |
| LRI Investments, LLC | 0.00% | No change | 1 | $57 |
| Huntington National Bank | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is NKTR's weight in each manager's 13F, not the share of Nektar Therapeutics the manager owns.